FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033163923> ?p ?o ?g. }

• W3033163923 endingPage "175883592092679" @default.
• W3033163923 startingPage "175883592092679" @default.
• W3033163923 abstract "Background: YYB101, a humanized monoclonal antibody against hepatocyte growth factor (HGF), has shown safety and efficacy in vitro and in vivo. This is a first-in-human trial of this antibody. Materials and Methods: YYB101 was administered intravenously to refractory cancer patients once every 4 weeks for 1 month, and then once every 2 weeks until disease progression or intolerable toxicity, at doses of 0.3, 1, 3, 5, 10, 20, 30 mg/kg, according to a 3+3 dose escalation design. Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were studied. HGF, MET, PD-L1, and ERK expression was evaluated for 9 of 17 patients of the expansion cohort (20 mg/kg). Results: In 39 patients enrolled, no dose-limiting toxicity was observed at 0.3 mg/kg, and the most commonly detected toxicity was generalized edema ( n = 7, 18.9%) followed by pruritis and nausea ( n = 5, 13.5%, each), fatigue, anemia, and decreased appetite ( n = 4, 10.8%, each). No patient discontinued treatment because of adverse events. YYB101 showed dose-proportional pharmacokinetics up to 30 mg/kg. Partial response in 1 (2.5%) and stable disease in 17 (43.5%) were observed. HGF, MET, PD-L1, and ERK proteins were not significant predictors for treatment response. However, serum HGF level was significantly lowered in responders upon drug administration. RNA sequencing revealed a mesenchymal signature in two long-term responders. Conclusion: YYB101 showed favorable safety and efficacy in patients with refractory solid tumors. Based on this phase I trial, a phase II study on the YYB101 + irinotecan combination in refractory metastatic colorectal cancer patients is planned. Conclusion: ClinicalTrials.gov Identifier: NCT02499224" @default.
• W3033163923 created "2020-06-12" @default.
• W3033163923 creator A5003082249 @default.
• W3033163923 creator A5005100602 @default.
• W3033163923 creator A5005933314 @default.
• W3033163923 creator A5013311116 @default.
• W3033163923 creator A5014768069 @default.
• W3033163923 creator A5015598872 @default.
• W3033163923 creator A5016244479 @default.
• W3033163923 creator A5018929039 @default.
• W3033163923 creator A5026351538 @default.
• W3033163923 creator A5030107272 @default.
• W3033163923 creator A5035817927 @default.
• W3033163923 creator A5045587524 @default.
• W3033163923 creator A5057146015 @default.
• W3033163923 creator A5062509934 @default.
• W3033163923 creator A5062957280 @default.
• W3033163923 creator A5065244228 @default.
• W3033163923 creator A5068494719 @default.
• W3033163923 date "2020-01-01" @default.
• W3033163923 modified "2023-09-25" @default.
• W3033163923 title "First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients" @default.
• W3033163923 cites W1975777116 @default.
• W3033163923 cites W1975871632 @default.
• W3033163923 cites W1986250311 @default.
• W3033163923 cites W1987815989 @default.
• W3033163923 cites W2054042846 @default.
• W3033163923 cites W2055191970 @default.
• W3033163923 cites W2076633367 @default.
• W3033163923 cites W2087352606 @default.
• W3033163923 cites W2094337993 @default.
• W3033163923 cites W2099221592 @default.
• W3033163923 cites W2137391343 @default.
• W3033163923 cites W2166208962 @default.
• W3033163923 cites W2232996102 @default.
• W3033163923 cites W2598809873 @default.
• W3033163923 cites W2605963676 @default.
• W3033163923 cites W2724682849 @default.
• W3033163923 cites W2743492635 @default.
• W3033163923 cites W2758552192 @default.
• W3033163923 cites W2763498516 @default.
• W3033163923 cites W2791756039 @default.
• W3033163923 cites W2792099291 @default.
• W3033163923 cites W2792883124 @default.
• W3033163923 cites W2811503321 @default.
• W3033163923 cites W2884397450 @default.
• W3033163923 cites W2946212280 @default.
• W3033163923 cites W2952156647 @default.
• W3033163923 cites W2958696665 @default.
• W3033163923 doi "https://doi.org/10.1177/1758835920926796" @default.
• W3033163923 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7268171" @default.
• W3033163923 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32536979" @default.
• W3033163923 hasPublicationYear "2020" @default.
• W3033163923 type Work @default.
• W3033163923 sameAs 3033163923 @default.
• W3033163923 citedByCount "9" @default.
• W3033163923 countsByYear W30331639232019 @default.
• W3033163923 countsByYear W30331639232020 @default.
• W3033163923 countsByYear W30331639232021 @default.
• W3033163923 countsByYear W30331639232022 @default.
• W3033163923 countsByYear W30331639232023 @default.
• W3033163923 crossrefType "journal-article" @default.
• W3033163923 hasAuthorship W3033163923A5003082249 @default.
• W3033163923 hasAuthorship W3033163923A5005100602 @default.
• W3033163923 hasAuthorship W3033163923A5005933314 @default.
• W3033163923 hasAuthorship W3033163923A5013311116 @default.
• W3033163923 hasAuthorship W3033163923A5014768069 @default.
• W3033163923 hasAuthorship W3033163923A5015598872 @default.
• W3033163923 hasAuthorship W3033163923A5016244479 @default.
• W3033163923 hasAuthorship W3033163923A5018929039 @default.
• W3033163923 hasAuthorship W3033163923A5026351538 @default.
• W3033163923 hasAuthorship W3033163923A5030107272 @default.
• W3033163923 hasAuthorship W3033163923A5035817927 @default.
• W3033163923 hasAuthorship W3033163923A5045587524 @default.
• W3033163923 hasAuthorship W3033163923A5057146015 @default.
• W3033163923 hasAuthorship W3033163923A5062509934 @default.
• W3033163923 hasAuthorship W3033163923A5062957280 @default.
• W3033163923 hasAuthorship W3033163923A5065244228 @default.
• W3033163923 hasAuthorship W3033163923A5068494719 @default.
• W3033163923 hasBestOaLocation W30331639231 @default.
• W3033163923 hasConcept C111113717 @default.
• W3033163923 hasConcept C112705442 @default.
• W3033163923 hasConcept C121332964 @default.
• W3033163923 hasConcept C126322002 @default.
• W3033163923 hasConcept C142424586 @default.
• W3033163923 hasConcept C143998085 @default.
• W3033163923 hasConcept C170493617 @default.
• W3033163923 hasConcept C197934379 @default.
• W3033163923 hasConcept C2776996007 @default.
• W3033163923 hasConcept C2780580376 @default.
• W3033163923 hasConcept C29730261 @default.
• W3033163923 hasConcept C71924100 @default.
• W3033163923 hasConcept C87355193 @default.
• W3033163923 hasConcept C90924648 @default.
• W3033163923 hasConcept C98274493 @default.
• W3033163923 hasConceptScore W3033163923C111113717 @default.
• W3033163923 hasConceptScore W3033163923C112705442 @default.
• W3033163923 hasConceptScore W3033163923C121332964 @default.

• next